Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Oral Health
Published in: BMC Oral Health 1/2021

01-12-2021 | Research

Nomogram based on clinical characteristics and serological inflammation markers to predict overall survival of oral tongue squamous cell carcinoma patient after surgery

Authors: Yi-Wei Lin, Wei-Piao Kang, Bin-Liang Huang, Zi-Han Qiu, Lai-Feng Wei, Biao Zhang, Tian-Yan Ding, Yun Luo, Can-Tong Liu, Ling-Yu Chu, Hai-Peng Guo, Yi-Wei Xu, Yu-Hui Peng

Published in: BMC Oral Health | Issue 1/2021

Login to get access

Abstract

Background

Oral tongue squamous cell carcinoma (OTSCC) is a prevalent malignant disease that is characterized by high rates of metastasis and postoperative recurrence. The aim of this study was to establish a nomogram to predict the outcome of OTSCC patients after surgery.

Methods

We retrospectively analyzed 169 OTSCC patients who underwent treatments in the Cancer Hospital of Shantou University Medical College from 2008 to 2019. The Cox regression analysis was performed to determine the independent prognostic factors associated with patient’s overall survival (OS). A nomogram based on these prognostic factors was established and internally validated using a bootstrap resampling method.

Results

Multivariate Cox regression analysis revealed the independent prognostic factors for OS were TNM stage, age, lymphocyte-to-monocyte ratio and immunoglobulin G, all of which were identified to create the nomogram. The Akaike Information Criterion and Bayesian Information Criterion of the nomogram were lower than those of TNM stage (292.222 vs. 305.480; 298.444 vs. 307.036, respectively), indicating a better goodness-of-fit of the nomogram for predicting OS. The bootstrap-corrected of concordance index (C-index) of nomogram was 0.784 (95% CI 0.708–0.860), which was higher than that of TNM stage (0.685, 95% CI 0.603–0.767, P = 0.017). The results of time-dependent C-index for OS also showed that the nomogram had a better discriminative ability than that of TNM stage. The calibration curves of the nomogram showed good consistency between the probabilities and observed values. The decision curve analysis also revealed the potential clinical usefulness of the nomogram. Based on the cutoff value obtained from the nomogram, the proposed high-risk group had poorer OS than low-risk group (P < 0.0001).

Conclusions

The nomogram based on clinical characteristics and serological inflammation markers might be useful for outcome prediction of OTSCC patient.
Literature
1.
Ng JH, Iyer NG, Tan MH, Edgren G. Changing epidemiology of oral squamous cell carcinoma of the tongue: a global study. Head Neck. 2017;39(2):297–304.PubMed
2.
Li Y, Zhao Z, Liu X, Ju J, Chai J, Ni Q, et al. Nomograms to estimate long-term overall survival and tongue cancer-specific survival of patients with tongue squamous cell carcinoma. Cancer Med. 2017;6(5):1002–13.PubMedPubMedCentral
3.
Riemann M, Knipfer C, Rohde M, Adler W, Schuster M, Noeth E, et al. Oral squamous cell carcinoma of the tongue: prospective and objective speech evaluation of patients undergoing surgical therapy. Head Neck. 2016;38(7):993–1001.PubMed
4.
Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet. 2002;360(9340):1131–5.PubMed
5.
Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer. 2005;103(9):1843–9.PubMed
6.
Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80.PubMedPubMedCentral
7.
Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.PubMed
8.
Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10(11):1045–52.PubMedPubMedCentral
9.
Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013;14(13):1295–306.PubMed
10.
Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21(19):3647–50.PubMed
11.
Kattan MW, Gönen M, Jarnagin WR, DeMatteo R, D’Angelica M, Weiser M, et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247(2):282–7.PubMed
12.
Zivanovic O, Jacks LM, Iasonos A, Leitao MM Jr, Soslow RA, Veras E, et al. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer. 2012;118(3):660–9.PubMed
13.
Yang L, Takimoto T, Fujimoto J. Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma. BMC Cancer. 2014;14:654.PubMedPubMedCentral
14.
Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33(Suppl 1):S79-84.PubMed
15.
Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):971–8.PubMed
16.
Li W, Tao L, Zhang L, Xiu D. Prognostic role of lymphocyte to monocyte ratio for patients with pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:3391–7.PubMedPubMedCentral
17.
Tan D, Fu Y, Tong W, Li F. Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: a meta-analysis. Int J Surg. 2018;55:128–38.PubMed
18.
Mao Y, Chen D, Duan S, Zhao Y, Wu C, Zhu F, et al. Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis. Cancer Cell Int. 2018;18:201.PubMedPubMedCentral
19.
Sollie S, Santaolalla A, Michaud DS, Sarker D, Karagiannis SN, Josephs DH, et al. Serum immunoglobulin G is associated with decreased risk of pancreatic cancer in the Swedish AMORIS Study. Front Oncol. 2020;10:263.PubMedPubMedCentral
20.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.PubMed
21.
Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.PubMed
22.
Lu Z, Yan W, Liang J, Yu M, Liu J, Hao J, et al. Nomogram based on systemic immune-inflammation index to predict survival of tongue cancer patients who underwent cervical dissection. Front Oncol. 2020;10:341.PubMedPubMedCentral
23.
Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493-503.PubMed
24.
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–81.PubMed
25.
Furukawa K, Kawasaki G, Naruse T, Umeda M. Prognostic significance of pretreatment lymphocyte-to-monocyte ratio in patients with tongue cancer. Anticancer Res. 2019;39(1):405–12.PubMed
26.
Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–55.PubMed
27.
Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.PubMedPubMedCentral
28.
Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–91.PubMedPubMedCentral
29.
Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93(3):273–8.PubMedPubMedCentral
30.
Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, et al. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol. 2012;124(1):92–7.PubMed
31.
Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep. 2005;14(2):425–31.PubMed
32.
Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362(10):875–85.PubMedPubMedCentral
33.
Lin S, Wang Y, Wang X, Yan B, Lou W, Di W. Serum immunoglobulin G N-glycome: a potential biomarker in endometrial cancer. Ann Transl Med. 2020;8(12):748.PubMedPubMedCentral
34.
Yi CH, Weng HL, Zhou FG, Fang M, Ji J, Cheng C, et al. Elevated core-fucosylated IgG is a new marker for hepatitis B virus-related hepatocellular carcinoma. Oncoimmunology. 2015;4(12):e1011503.PubMedPubMedCentral
35.
Vučković F, Theodoratou E, Thaçi K, Timofeeva M, Vojta A, Štambuk J, et al. IgG glycome in colorectal cancer. Clin Cancer Res. 2016;22(12):3078–86.PubMedPubMedCentral
36.
Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol. 2018;333:65–79.PubMed
37.
Kessler A, Sollie S, Karagiannis SN, Walldius G, Hammar N, Van Hemelrijck M. Serum IgG is associated with risk of melanoma in the Swedish AMORIS study. Front Oncol. 2019;9:1095.PubMedPubMedCentral
38.
Sun W, Cheng M, Zhuang S, Chen H, Yang S, Qiu Z. Nomograms to predict survival of stage IV tongue squamous cell carcinoma after surgery. Medicine (Baltimore). 2019;98(26):e16206.
39.
Saenthaveesuk P, Yang L, Zeng B, Xu M, Young S, Liao G, et al. Development and validation of multiparametric MRI-based nomogram for predicting occult metastasis risk in early tongue squamous cell carcinoma. BMC Cancer. 2021;21(1):408.PubMedPubMedCentral
40.
Mair M, Nair D, Nair S, Malik A, Mishra A, Kannan S, et al. Comparison of tumor volume, thickness, and T classification as predictors of outcomes in surgically treated squamous cell carcinoma of the oral tongue. Head Neck. 2018;40(8):1667–75.PubMed
41.
Balasubramanian D, Subramaniam N, Missale F, Marchi F, Dokhe Y, Vijayan S, et al. Predictive nomograms for oral tongue squamous cell carcinoma applying the American Joint Committee on Cancer/Union Internationale Contre le Cancer 8th edition staging system. Head Neck. 2021;43(4):1043–55.PubMed
42.
43.
Chang B, He W, Ouyang H, Peng J, Shen L, Wang A, et al. A prognostic nomogram incorporating depth of tumor invasion to predict long-term overall survival for tongue squamous cell carcinoma with R0 resection. J Cancer. 2018;9(12):2107–15.PubMedPubMedCentral
44.
Mascitti M, Zhurakivska K, Togni L, Caponio VCA, Almangush A. Addition of the tumour-stroma ratio to the 8th edition American Joint Committee on Cancer staging system improves survival prediction for patients with oral tongue squamous cell carcinoma. Histopathology. 2020;77(5):810–22.PubMed
45.
Jiang Q, Tang A, Long S, Qi Q, Song C, Xin Y, et al. Development and validation of a nomogram to predict the risk of occult cervical lymph node metastases in cN0 squamous cell carcinoma of the tongue. Br J Oral Maxillofac Surg. 2019;57(10):1092–7.PubMed
46.
47.
Abbate V, Dell’Aversana Orabona G, Salzano G, Bonavolontà P, Maglitto F, Romano A, et al. Pre-treatment Neutrophil-to-Lymphocyte Ratio as a predictor for occult cervical metastasis in early stage (T1–T2 cN0) squamous cell carcinoma of the oral tongue. Surg Oncol. 2018;27(3):503–7.PubMed
48.
Wu CN, Chuang HC, Lin YT, Fang FM, Li SH, Chien CY. Prognosis of neutrophil-to-lymphocyte ratio in clinical early-stage tongue (cT1/T2N0) cancer. Onco Targets Ther. 2017;10:3917–24.PubMedPubMedCentral
49.
50.
Peppas I, George G, Sollie S, Josephs DH, Hammar N, Walldius G, et al. Association of serum immunoglobulin levels with solid cancer: a systematic review and meta-analysis. Cancer Epidemiol Prev Biomark. 2020;29(3):527–38.
51.
Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ, Shoenfeld Y. Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol. 2009;158(Suppl 1):43–50.PubMedPubMedCentral
52.
Riihilä P, Nissinen L, Farshchian M, Kallajoki M, Kivisaari A, Meri S, et al. Complement component C3 and complement factor B promote growth of cutaneous squamous cell carcinoma. Am J Pathol. 2017;187(5):1186–97.PubMed
53.
Kim SH, Lee MJ, Hwang HK, Lee SH, Kim H, Paik YK, et al. Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: a pilot study. Cancer Biomark. 2019;24(3):335–42.PubMed
54.
55.
Ajona D, Ortiz-Espinosa S, Pio R. Complement anaphylatoxins C3a and C5a: emerging roles in cancer progression and treatment. Semin Cell Dev Biol. 2019;85:153–63.PubMed
56.
Ling M, Murali M. Analysis of the Complement System in the Clinical Immunology Laboratory. Clin Lab Med. 2019;39(4):579–90.PubMed
Metadata
Title
Nomogram based on clinical characteristics and serological inflammation markers to predict overall survival of oral tongue squamous cell carcinoma patient after surgery
Authors
Yi-Wei Lin
Wei-Piao Kang
Bin-Liang Huang
Zi-Han Qiu
Lai-Feng Wei
Biao Zhang
Tian-Yan Ding
Yun Luo
Can-Tong Liu
Ling-Yu Chu
Hai-Peng Guo
Yi-Wei Xu
Yu-Hui Peng
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Oral Health / Issue 1/2021
Electronic ISSN: 1472-6831
DOI
https://doi.org/10.1186/s12903-021-02028-7

Other articles of this Issue 1/2021

BMC Oral Health 1/2021 Go to the issue

Research

Classifying and standardizing panfacial trauma according to anatomic categories and Facial Injury Severity Scale: a 10-year retrospective study

Case report

Primary oral mucosa-associated lymphoid tissue (MALT) lymphoma in patient with monoclonale gammopathy: a rare case report

Research

Tooth alignment and pain experience with A-NiTi versus Cu-NiTi: a randomized clinical trial

Research article

Scoping review of trials evaluating adhesive strategies in pediatric dentistry: where do simplified strategies lie?

Research

Serum 8-isoprostane levels in patients with resistant oral lichen planus before and after treatment with lycopene: a randomized clinical trial

Research article

Effects of immediate and delayed loading protocols on marginal bone loss around implants in unsplinted mandibular implant-retained overdentures: a systematic review and meta-analysis